The Drug Enforcement Administration and Department of Health and Human Services Nov. 15 issued a final rule extending certain telemedicine prescribing flexibilities for an additional year. As urged by the AHA, the agencies will waive the in-person visit requirement prior to the prescribing of controlled substances virtually until Dec. 31, 2025. The flexibilities were granted during the COVID-19 public health emergency and were set to expire at the end of this year.

Related News Articles

Headline
In comments Nov. 12 to majority and minority leaders of the House and Senate, the AHA requested that Congress act on key priorities for hospitals and health…
Headline
In this conversation, Johnna Nynas, M.D., obstetrician and gynecologist at Sanford Health Bemidji, discusses the dramatic expansion of maternal telehealth…
Headline
The Centers for Medicare & Medicaid Services Nov. 1 released its calendar year 2025 final rule for the physician fee schedule. The rule will cut the…
Perspective
People want medical care that is safe, convenient and accessible. Hospitals deliver that every day within their walls — and increasingly, outside of their…
Headline
The AHA Oct. 4 urged the Drug Enforcement Administration and Department of Health and Human Services to extend telehealth flexibilities an additional two years…
Headline
The House Energy and Commerce Committee Sept. 18 advanced legislation on expiring telehealth and hospital-at-home flexibilities. The AHA supported the passage…